Metformin Targeting in Osteoarthritis Management

Osteoarthritis (OA) is a prevalent degenerative joint disorder characterised by cartilage breakdown, subchondral bone remodelling and chronic pain. Traditional management focuses on symptom relief, but the search for disease-modifying agents has intensified. Metformin, a biguanide widely used in type 2 diabetes, has emerged as a candidate for OA intervention owing to its capacity to activate the energy sensor adenosine monophosphate-activated protein kinase (AMPK), modulate inflammatory pathways, and enhance autophagy. By restoring chondrocyte homeostasis, reducing catabolic enzyme production and attenuating inflammatory mediators, metformin demonstrates cartilage-protective effects in preclinical models. Clinical and observational studies further suggest that metformin may slow cartilage degeneration, improve pain and function, and decrease the need for joint replacement in obese patients with knee OA. These findings point to metformin’s potential as a safe, cost-effective adjuvant that targets fundamental mechanisms of OA pathogenesis, offering prospects for global therapeutic impact.

Research from Nature Portfolio

Recent mechanistic research utilising cartilage-specific knockout mouse models has elucidated the central role of AMPK in maintaining joint integrity. Conditional deletion of AMPKα isoforms in chondrocytes accelerated surgically induced and age-related OA, marked by heightened inflammatory signalling, increased expression of matrix metalloproteinases and elevated chondrocyte apoptosis. These findings underscore that AMPK activation is essential for resisting cartilage degradation and that pharmacological stimulators of this pathway—such as metformin—may counteract OA progression by restoring cellular energy balance and inhibiting catabolic responses.

Metformin Targeting in Osteoarthritis Management publication trend

The graph below shows the total number of articles in metformin targeting in osteoarthritis management across all publications each year (not limited to Nature Index journals).

Technical terms

AMP-activated protein kinase (AMPK): A cellular energy sensor kinase that regulates metabolism, inflammation and autophagy in chondrocytes.

Autophagy: A regulated mechanism for the degradation and recycling of cellular components, essential for chondrocyte survival under stress.

Chondrocyte: The specialised cell type found in cartilage responsible for extracellular matrix maintenance.

Matrix metalloproteinase 13 (MMP-13): A catabolic enzyme that degrades type II collagen, contributing to cartilage breakdown in OA.

Sirtuin 1 (SIRT1): A nicotinamide adenine dinucleotide-dependent deacetylase that interacts with AMPK to promote autophagy and protect against cellular senescence.

References

1. Metformin as adjuvant therapy in obese knee osteoarthritis patients. Inflammopharmacology (2024).
2. AMPK deficiency in chondrocytes accelerated the progression of instability-induced and ageing-associated osteoarthritis in adult mice. Scientific Reports (2017).
3. Association between metformin use and disease progression in obese people with knee osteoarthritis: data from the Osteoarthritis Initiative—a prospective cohort study. Arthritis Research & Therapy (2019).
4. Exploration of metformin as novel therapy for osteoarthritis: preventing cartilage degeneration and reducing pain behavior. Arthritis Research & Therapy (2020).